新的血蛋白C和蛋白S缩物:用于治疗目的的协同作用
Filippo Mori1, Cristina Angelini1, Claudio Farina1
1Department of Research and Innovation, Kedrion Biopharma, Bolognana, Italy.
Vox sanguinis
|November 29, 2023
概括
从血分离废物中开发出一种新的蛋白C (PC) 和蛋白S (PS) 缩物. 这种缩剂为新生儿紫色满症提供了潜在的治疗选择,改善了治疗的可用性.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 血蛋白治疗药物 血蛋白治疗药物
背景情况:
- 蛋白C (PC) 和蛋白S (PS) 缺乏是罕见的遗传疾病,导致危及生命的新生儿紫外线.
- 目前的治疗依赖于替代疗法,可使用PC缩剂,但不能使用PC/PS缩剂组合.
- 严重PS缺乏症的治疗方法有限,这凸显了对替代治疗方案的需求.
研究的目的:
- 开发一种新的,具有成本效益的蛋白C/蛋白S (PC/PS) 缩物,由血分离中间体制成.
- 建立适用于治疗用途的PC/PS联合缩物的净化工艺.
- 为解决严重蛋白质S缺乏症治疗的未满足需求.
主要方法:
- 在血分离中间体上使用染色学技术来隔离和净化PC/PS.
- 根据特定活动和恢复率选择最佳色谱支.
- 建立了一个全面的净化过程,包括病毒无活化/去除和冷化.
主要成果:
- 开发出一个冷干燥的PC/PS缩物,平均PC度为47.75 IU/mL和11%PS.
- 实现了202.5 IU/mg蛋白质的平均特异活性,代表了超过12,000倍的净化.
- 证明了从废物分数中生产高度净化的PC/PS混合物的可行性.
结论:
- 从等离子体加工的副产品中可以生产出一种新的缩PC/PS混合物.
- 这种PC/PS缩物具有潜在的治疗价值,用于治疗新生儿紫外线.
- 这种发展可能会降低制造成本,并改善治疗的可访问性.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
711
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
711
Combined Effects of Drugs: Synergism
3.9K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.9K
Drug Distribution: Plasma Protein Binding
5.7K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.7K


